Urethane is widely used for its ability to induce prolonged anesthesia. Variability in previously reported cardiovascular parameters in murine models makes it challenging to definitively evaluate the cardiovascular effects of urethane anesthesia. We aimed to address these challenges, thereby advancing our understanding of urethane's effects on cardiovascular function in mice. In this study, we investigated how urethane anesthesia, with and without supplemental oxygen, impacts heart rate, arterial oxygen saturation ([Formula: see text]), blood pressure, and heart rate variability in mice. First, we conducted a literature review and found that data in mice were both limited and lacking in reproduction. Next, we conducted a series of physiological measurements to address gaps in the literature and subjected C57BL/6J mice to three conditions: ) conscious, ) urethane-anesthetized, and ) urethane-anesthetized with supplemental oxygen. Blood pressure, heart rate, [Formula: see text], and heart rate variability (via time, frequency, and M-curve analyses) were assessed. We observed an increase in heart rate with urethane anesthesia ( = 0.012) compared with the conscious state. Urethane caused a decrease in heart rate variability, which was independent of oxygen supplementation. Urethane anesthesia caused a significant reduction in arterial blood pressure ( < 0.001) with oxygen-supplemented mice remained hypotensive. Urethane decreased [Formula: see text] ( = 0.001), which was restored by oxygen supplementation ( < 0.001). We did not observe sex effects of urethane anesthesia on blood pressure, heart rate, heart rate variability, or [Formula: see text]. Taken together, these results underscore the importance of a cautious approach when using urethane in mice, as urethane significantly impacts arterial blood pressure, heart rate, oxygen saturation, and heart rate variability. This investigation documents cardiovascular outcomes in mice receiving urethane anesthesia, emphasizing sex as a biological variable, and considering oxygen supplementation during anesthesia. This is the first report of M-curve analysis in rodents as a heart rate-independent variability analysis.

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpregu.00097.2024DOI Listing

Publication Analysis

Top Keywords

heart rate
40
urethane anesthesia
24
blood pressure
20
rate variability
20
[formula text]
16
pressure heart
16
oxygen supplementation
12
urethane
11
heart
11
rate
10

Similar Publications

Cardiac acetylcholinesterase and butyrylcholinesterase have distinct localization and function.

Am J Physiol Heart Circ Physiol

January 2025

Comenius University Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovakia.

Cholinesterase (ChE) inhibitors are under consideration to be used in the treatment of cardiovascular pathologies. A prerequisite to advancing ChE inhibitors into the clinic is their thorough characterization in the heart. The aim here was to provide a detailed analysis of cardiac ChE to understand their molecular composition, localization, and physiological functions.

View Article and Find Full Text PDF

The duration of mechanical systole-also termed the flow time (FT) or left ventricular ejection time (LVET)-is measured by Doppler ultrasound and increasingly used as a stroke volume (SV) surrogate to guide patient care. Nevertheless, confusion exists as to the determinants of FT and a critical evaluation of this measure is needed. Using Doppler ultrasound of the left ventricular outflow tract velocity time integral (LVOT VTI) as well as strain and strain rate echocardiography as grounding principles, this brief commentary offers a model for the independent influences of FT.

View Article and Find Full Text PDF

Introduction: Obstructive sleep apnoea (OSA) in children is associated with numerous adverse outcomes, including elevated blood pressure. While the associations between OSA, obesity, and autonomic dysfunction are recognised, the precise mechanisms linking these factors and their relationship with elevated blood pressure in children remain unclear.

Methods: This retrospective case series included 76 children with OSA.

View Article and Find Full Text PDF

Background: GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited.

Objectives: To assess the safety and efficacy of GLP-1 RA in durable LVAD patients.

View Article and Find Full Text PDF

Pimobendan oral solution is bioequivalent to pimobendan chewable tablets in beagle dogs.

J Vet Intern Med

January 2025

Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, Germany.

Background: Myxomatous mitral valve disease (MMVD) is frequently diagnosed in small breed dogs. Pimobendan oral solution has been developed to improve dosing accuracy in small and toy breed dogs.

Hypothesis/objectives: Demonstrate bioequivalence of pimobendan oral solution with pimobendan chewable tablets using a pharmacokinetic and a pharmacodynamic study in healthy purpose bred dogs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!